Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a...

Keywords

ErlotinibMedicineDocetaxelInternal medicineLung cancerHazard ratioOncologyClinical endpointChemotherapyPopulationErlotinib HydrochloridePerformance statusRandomized controlled trialCancerConfidence intervalEpidermal growth factor receptor

Affiliated Institutions

Related Publications

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Pui San Tan , Gilberto Lopes , Sanchalika Acharyya +2 more

Maintenance treatments show clinically meaningful survival benefits in good performance status patients with advanced NSCLC not progressing after first-line chemotherapy. Benefi...

2015 European Journal of Cancer 17 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck , Delvys Rodríguez‐Abreu , Andrew Robinson +15 more

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

2016 New England Journal of Medicine 9645 citations

The National Lung Screening Trial: Overview and Study Design

Constantine A. Gatsonis , Denise R. Aberle , Christine D. Berg +97 more

The National Lung Screening Trial (NLST) is a randomized multicenter study comparing low-dose helical computed tomography (CT) with chest radiography in the screening of older c...

2010 Radiology 1227 citations

Management of Lung Nodules Detected by Volume CT Scanning

Rob J. van Klaveren , Matthijs Oudkerk , Mathias Prokop +24 more

Among subjects at high risk for lung cancer who were screened in three rounds of CT scanning and in whom noncalcified pulmonary nodules were evaluated according to volume and vo...

2009 New England Journal of Medicine 814 citations

Publication Info

Year: 2013
Type: article
Volume: 14
Issue: 10
Pages: 981-988
Citations: 475
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

475

OpenAlex

Cite This

APA Style

                            
                                
                                    Marina Chiara Garassino, 
                                
                                    Olga Martelli, 
                                
                                    Massimo Broggini
                                
                                et al.
                            
                            (2013). 
                            Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. 
                            The Lancet Oncology
                            , 14
                            (10)
                            , 981-988.
                            https://doi.org/10.1016/s1470-2045(13)70310-3
                        

Identifiers

DOI: 10.1016/s1470-2045(13)70310-3